Companies / Nevada / Volitionrx

· rebuilt nightly from public records

Signal Sheet

Selling to Volitionrx? Who to reach and why now

Henderson, Nevada is home to Volitionrx, a publicly listed in vitro & in vivo diagnostic substances company. It raised $16.2M in May 2025 and its filings name 18 officers. Everything below links to the record it came from.

Listed company · In Vitro & In Vivo Diagnostic Substances · Nevada

The easy button for new customers

Lakewave's AI keeps accounts like this one coming. Your pipeline refills while you sleep.

Every night it scans funding, filings, new officers, hiring, contracts, permits and bids, finds the accounts that fit what you sell, and delivers each with outreach and a pursuit plan. Just need a list? Its AI waterfall builds one with verified, reachable contacts.

SourceNew accounts that match what you offer, added as the signals land. The list never runs dry.
Reach outA first email written from why the account is hot, then a drip sequence that follows up until they reply. Sent from your own mailbox, with every open and reply tracked.
PursueAn AI-written plan built from your value proposition and the customer's compelling event: who to call, what to lead with, and the next step to win it. In early access.
Start your free trial →Tell it what you sell and where. Your list stays yours.

Who to reach

The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names

RoleContactSourceWhy they matter now
Executive OfficerCameron ReynoldsSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerTerig HughesSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerRodney RootsaertSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerLouise BatchelorSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerSalvatore Thomas ButeraSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerGael ForterreSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerJasmine KwaySEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerJacob MicallefSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerGaetan MichelSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerNicholas PlummerSEC filing, May 2025Named officer in the filing; part of the buying group
Executive OfficerAndrew RetterSEC filing, May 2025Named officer in the filing; part of the buying group
Chief Technology OfficerAlan ColmanSEC filing, May 2025Technology and tooling decisions
Chief Technology OfficerMickie HenshallSEC filing, May 2025Technology and tooling decisions
Chief Technology OfficerGuy Archibald InnesSEC filing, May 2025Technology and tooling decisions
Chief Technology OfficerKim NguyenSEC filing, May 2025Technology and tooling decisions
Chief Technology OfficerPhillip BarnesSEC filing, May 2025Technology and tooling decisions
Chief Technology OfficerTimothy I StillSEC filing, May 2025Technology and tooling decisions
Chief Technology OfficerEthel RubinSEC filing, May 2025Technology and tooling decisions
For sellersWhy Volitionrx is worth a call this quarterBuy Window: open · new leadership Nov 2026
Nov 10Nov 2026

New leadership

Officer or director change

New leadership
Oct 2026Oct 2026

Corporate event

Signed a material agreement

Corporate event
$16.2M

Raised

Equity raise reported to the SEC, May 2025. Money arrives before the spending plan does.

Capital
Track Volitionrx with a free trial →Get the next signal the day it is filed or posted.
Email me the next Volitionrx signalOne email when it files, raises, hires or posts a role. Watch up to 3 companies free, no password.

Why now

The most recent events first, refreshed every night. Each links to the record it came from.

WhenWhat happenedKindSource
Nov 10, 2026Officer or director changeNew leadershipSEC filing
Oct 23, 2026Signed a material agreementCorporate eventSEC filing
Sep 2, 2026Signed a material agreementCorporate eventSEC filing
May 20, 2025Raised $16.2M in equity from 1 investorsCapitalSEC filing

Reach Volitionrx with emails that land

Lakewave finds the right people at Volitionrx, checks every address against the mail server before you see it, and drafts a first email for each, which you review and send from your own inbox.

Try it on Volitionrx with a free trial →

About Volitionrx

HeadquartersHenderson, Nevada, per the filing address
Industry groupIn Vitro & In Vivo Diagnostic Substances
OwnershipListed company
Raise history$16.2M (May 2025)
Lakewave Rising34 · 2 kinds of evidence · rank in Nevada after sign-up

Questions people ask

Did Volitionrx raise funding in 2025?

Yes. Volitionrx reported a $16.2M equity raise to the SEC on May 20, 2025 with 1 investors.

Who runs Volitionrx?

The company's SEC filing, May 2025 names Cameron Reynolds (Executive Officer) among its officers.

Where is Volitionrx headquartered?

Henderson, Nevada, per the address on its SEC filing.

Know who is buying before the first callStart your free trial →

Know who is buying before the first call

Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.

Start your free trial

Compiled from public records and refreshed nightly; last updated Nov 16, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.